BAO PHARMA-B (02659) announced that on July 27, 2026, it utilized HKD 1,284,900 to repurchase 70,600 of its own shares.
This move reflects the company's capital management strategy to return value to shareholders and signal confidence in its market position.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments